Experimental evidence for proarrhythmic mechanisms of antiarrhythmic drugs

Cardiovascular Research
S Nattel

Abstract

The major limitation to antiarrhythmic drug therapy is the risk of arrhythmia promotion, or 'proarrhythmia.' This complication may be lethal, and greatly restricts the value of antiarrhythmic agents, particularly for arrhythmias without an intrinsic mortality risk, such as atrial fibrillation. In order for improved antiarrhythmic drug therapy to be developed, it is essential to understand the fundamental mechanisms that cause proarrhythmic reactions to antiarrhythmic drugs. The present article reviews the experimental evidence that has been obtained regarding the mechanisms of proarrhythmia. The evidence available provides important insights, and points to potential strategies for developing newer and safer antiarrhythmic compounds.

Citations

Jun 23, 2000·European Journal of Pharmacology·T D BarrettM J Walker
Mar 25, 1999·Journal of Cardiovascular Electrophysiology·S Nattel
Feb 24, 2015·International Journal of Cardiology·David Y ChiangNa Li
Jan 17, 2015·Journal of the American College of Cardiology·David Y ChiangArjen Scholten
Nov 24, 1999·The American Journal of Cardiology·S Nattel, B N Singh
Jul 24, 2003·Journal of Cardiovascular Electrophysiology·Suresh SingarayarTerence Campbell
Nov 24, 2005·Journal of Cardiovascular Electrophysiology·David FedidaGregory N Beatch
Mar 21, 2007·Expert Opinion on Investigational Drugs·David Fedida
Jul 11, 2000·Japanese Journal of Pharmacology·J Tamargo
Apr 15, 2015·European Journal of Clinical Pharmacology·Juan TamargoPhillipe Mabo
Jul 5, 2016·Journal of Pharmacological and Toxicological Methods·Hua Rong LuGan-Xin Yan
Jan 24, 2006·Lancet·Stanley Nattel, Lionel H Opie
Jan 24, 2002·Nature·Stanley Nattel
Aug 20, 2004·American Journal of Physiology. Heart and Circulatory Physiology·Sarah J Canyon, Geoffrey P Dobson
Jun 22, 2018·Pacing and Clinical Electrophysiology : PACE·Po-Cheng ChangChung-Chuan Chou
Apr 27, 2005·Circulation·John A VestAndrew R Marks
Mar 4, 2020·Journal of the American Veterinary Medical Association·Hillary K Hammond, Sonja S Tjostheim
Mar 30, 2017·Science China. Life Sciences·Yufei WuYi-Han Chen
Aug 5, 2011·Clinical Pharmacology and Therapeutics·B CharbitC Funck-Brentano
Sep 29, 2019·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Liao-Yuan WangGuang-Yu Ji
Feb 25, 2021·Pflügers Archiv : European journal of physiology·Xiao-Dong ZhangNipavan Chiamvimonvat
Mar 23, 2021·Computational and Mathematical Methods in Medicine·Shengjue XiaoDefeng Pan
Sep 22, 2021·Journal of Cardiovascular Pharmacology and Therapeutics·Jeffrey L AndersonKirk U Knowlton

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.